Literature DB >> 21860675

MELD score, insulin-like growth factor 1 and cytokines on bone density in end-stage liver disease.

Rebecca Mitchell1, Jill McDermid, Mang M Ma, Constance L Chik.   

Abstract

AIM: To determine the contributions of insulin-like growth factor 1 (IGF-1), cytokines and liver disease severity to bone mineral density in patients pre-transplantation.
METHODS: Serum IGF-1, tumor necrosis factor-α (TNFα) and interleukin 6 (IL-6) were measured and the Model for End-Stage Liver Disease (MELD) score calculated in 121 adult patients referred to a single centre for liver transplantation. Bone mineral density (BMD) of the lumbar spine and femoral neck were assessed via dual energy X-ray absorptiometry. Demographics, liver disease etiology, medication use and relevant biochemistry were recorded.
RESULTS: A total of 117 subjects were included, with low BMD seen in 68.6%, irrespective of disease etiology. In multivariable analysis, low body mass index (BMI), increased bone turnover and low IGF-1 were independent predictors of low spinal bone density. At the hip, BMI, IGF-1 and vitamin D status were predictive. Despite prevalent elevations of TNFα and IL-6, levels did not correlate with degree of bone loss. The MELD score failed to predict low BMD in this pre-transplant population.
CONCLUSION: Osteopenia/osteoporosis is common in advanced liver disease. Low serum IGF-1 is weakly predictive but serum cytokine and MELD score fail to predict the severity of bone disease.

Entities:  

Keywords:  Bone mineral density; Cytokines; Hepatic osteodystrophy; Insulin-like growth factor-1; MELD score

Year:  2011        PMID: 21860675      PMCID: PMC3159496          DOI: 10.4254/wjh.v3.i6.157

Source DB:  PubMed          Journal:  World J Hepatol


  40 in total

1.  Interleukin-6 gene polymorphism is related to bone mineral density during and after puberty in healthy white males: a cross-sectional and longitudinal study.

Authors:  M Lorentzon; R Lorentzon; P Nordström
Journal:  J Bone Miner Res       Date:  2000-10       Impact factor: 6.741

2.  Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.

Authors:  J Genesca; A Gonzalez; R Segura; R Catalan; R Marti; E Varela; G Cadelina; M Martinez; J C Lopez-Talavera; R Esteban; R J Groszmann; J Guardia
Journal:  Am J Gastroenterol       Date:  1999-01       Impact factor: 10.864

3.  Circulating levels of insulin-like growth factors and their binding proteins in patients with chronic liver disease: lack of correlation with bone mineral density.

Authors:  S Ormarsdóttir; H Mallmin; H Olofsson; W F Blum; L Lööf
Journal:  Liver       Date:  2001-04

Review 4.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.

Authors:  S C Manolagas; R L Jilka
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

5.  Genetic factors determine extent of bone loss in inflammatory bowel disease.

Authors:  C M Schulte; A U Dignass; H Goebell; H D Röher; K M Schulte
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

6.  A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women.

Authors:  S L Ferrari; P Garnero; S Emond; H Montgomery; S E Humphries; S L Greenspan
Journal:  Arthritis Rheum       Date:  2001-01

7.  Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause.

Authors:  C Scheidt-Nave; H Bismar; G Leidig-Bruckner; H Woitge; M J Seibel; R Ziegler; J Pfeilschifter
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

8.  Bone mineral density among cirrhotic patients awaiting liver transplantation.

Authors:  Rana Paramvir Sokhi; Abhinandana Anantharaju; Ravi Kondaveeti; Steven D Creech; Khondker K Islam; David H Van Thiel
Journal:  Liver Transpl       Date:  2004-05       Impact factor: 5.799

9.  Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis.

Authors:  J A Jackson; M Kleerekoper; A M Parfitt; D S Rao; A R Villanueva; B Frame
Journal:  J Clin Endocrinol Metab       Date:  1987-07       Impact factor: 5.958

10.  Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients.

Authors:  A Khoruts; L Stahnke; C J McClain; G Logan; J I Allen
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

View more
  4 in total

Review 1.  Osteoporosis and bone fractures in alcoholic liver disease: a meta-analysis.

Authors:  Chang Seok Bang; In Soo Shin; Sung Wha Lee; Jin Bong Kim; Gwang Ho Baik; Ki Tae Suk; Jai Hoon Yoon; Yeon Soo Kim; Dong Joon Kim
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

2.  Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass.

Authors:  Zhongbo Liu; Tianzhen Han; Haim Werner; Clifford J Rosen; Mitchell B Schaffler; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2017-11-06       Impact factor: 6.741

3.  The role of serum cytokines in the pathogenesis of hepatic osteodystrophy in male cirrhotic patients.

Authors:  Ali Riza Soylu; Cengiz Tuglu; Ender Arikan; Tarkan Yetisyigit; Hakan Kunduracılar; Ibrahim Hakki Koker; Gulbin Unsal; Ahmet Huseyin Tezel; Hasan Umit; Sakir Berkarda
Journal:  Gastroenterol Res Pract       Date:  2012-10-14       Impact factor: 2.260

4.  Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Lianchun Xiao; Manal M Hassan; Young Kwang Chae; Ju-Seog Lee; Jean-Nicolas Vauthey; Sunil Krishnan; Sheree Cheung; Hesham M Hassabo; Thomas Aloia; Claudius Conrad; Steven A Curley; John M Vierling; Prasun Jalal; Kanwal Raghav; Michael Wallace; Asif Rashid; James L Abbruzzese; Robert A Wolff; Jeffrey S Morris
Journal:  J Natl Cancer Inst       Date:  2014-05-09       Impact factor: 13.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.